🔗 Share this article

As the US continues making historic revisions to its vaccination recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning COVID-19 vaccines in the pandemic and has concentrated on possible deaths after COVID-19 immunization in her recent position at the FDA.

Scheduled Overhauls to Pediatric Immunization Schedule

Agency leaders were set to unveil radical changes to the childhood immunization program recently, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would put the US out of step with many the world with little proof for public health gain. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad strengthen their influence at the agency – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending some pediatric shot schedules in the US so as to align more in line with the Danish model, a country with nationalized medicine and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – traditionally the purview of Prasad, director of the FDA’s CBER – rather than medication approval.

Questions Over Qualifications

The appointee has no obvious experience in pharmaceutical research, oversight or management, which has been customary for previous heads of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Previous directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who led the center have had.”

CDER has an immense portfolio at the FDA, the former commissioner pointed out.

“The public just focuses on the novel medication approvals, but the generic program approves a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one have to be supervised,” she explained. “The thing you neglect, that is the part that I always told people is going to bite you.”

There is also, a significant management component to the position, which supervises more than 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official said.

Official Statement and Contentious Initiatives

In response to questions about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “concerns stem from inaccurate assumptions”.

“Her resume is consistent with the duties of her job,” the official said, citing the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that reportedly concerned her former heads. “By what process are these drugs being picked for this fast-track system? Who takes the calls?” Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, except for immunizations.”

Public Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if problematic, history, critics said. She published a study using non-validated public submissions to assess the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the new administration featured revising guidelines for recently developed shots and discontinuing “non-essential” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding young men from receiving COVID-19 vaccinations.

“She’s an all-around true believer who commences with her conclusions and works backwards to accommodate the evidence in a very disingenuous, dishonest way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|